Genomic discoveries in adult astrocytoma

Current Opinion in Genetics and Development

Volumn 30, Issue , 2015, Pages 17-24

  Wang, Joanna ^a   Bettegowda, Chetan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; BEVACIZUMAB; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; IPILIMUMAB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NIVOLUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN TYROSINE KINASE; RAPAMYCIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RINDOPEPIMUT; SONOLISIB; TELOMERASE REVERSE TRANSCRIPTASE; ATRX PROTEIN, HUMAN; DNA HELICASE; EGFR PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NUCLEAR PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ASTROCYTOMA; ATRX GENE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EGFR GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENOME ANALYSIS; GLIOBLASTOMA; HUMAN; IDH1 GENE; IDH2 GENE; MULTIMODALITY CANCER THERAPY; NFKBIA GENE; NONHUMAN; PDGRFA GENE; REVIEW; SIGNAL TRANSDUCTION; TERT GENE; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

ADULT; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA HELICASES; HUMANS; ISOCITRATE DEHYDROGENASE; MOLECULAR TARGETED THERAPY; MUTATION; NUCLEAR PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 84921757952     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2014.12.002     Document Type: Review

References (66)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Grant R., Kolb L., Moliterno J. Molecular and genetic pathways in gliomas: the future of personalized therapeutics. CNS Oncol 2014, 3:123-136.
3. Tanaka S., Louis D.N., Curry W.T., Batchelor T.T., Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol 2013, 10:14-26.
4. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153.
5. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
6. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602.
7. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
8. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
9. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
10. Rakheja D., Medeiros L.J., Bevan S., Chen W. The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. Front Oncol 2013, 3:169.
11. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
12. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., Losman J.A., Joensuu P., Bergmann U., Gross S., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
13. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
14. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
15. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
16. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Xiao M.T., Liu L.X., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
17. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., Westphal M., Schackert G., Meyermann R., Pietsch T., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120:707-718.
18. Jiao Y., Killela P.J., Reitman Z.J., Rasheed A.B., Heaphy C.M., de Wilde R.F., Rodriguez F.J., Rosemberg S., Oba-Shinjo S.M., Nagahashi Marie S.K., et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012, 3:709-722.
19. Liu X.Y., Gerges N., Korshunov A., Sabha N., Khuong-Quang D.A., Fontebasso A.M., Fleming A., Hadjadj D., Schwartzentruber J., Majewski J., et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012, 124:615-625.
20. Wiestler B., Capper D., Holland-Letz T., Korshunov A., von Deimling A., Pfister S.M., Platten M., Weller M., Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013, 126:443-451.
21. Gan H.K., Kaye A.H., Luwor R.B. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009, 16:748-754.
22. Vogt N., Lefevre S.H., Apiou F., Dutrillaux A.M., Cor A., Leuraud P., Poupon M.F., Dutrillaux B., Debatisse M., Malfoy B. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci U S A 2004, 101:11368-11373.
23. Vivanco I., Rohle D., Versele M., Iwanami A., Kuga D., Oldrini B., Tanaka K., Dang J., Kubek S., Palaskas N., et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 2010, 107:6459-6464.
24. Cloughesy T.F., Cavenee W.K., Mischel P.S. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014, 9:1-25.
25. Frattini V., Trifonov V., Chan J.M., Castano A., Lia M., Abate F., Keir S.T., Ji A.X., Zoppoli P., Niola F., et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141-1149.
26. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
27. Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013, 126:931-937.
28. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., Friedman A.H., Friedman H., Gallia G.L., Giovanella B.C., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013, 110:6021-6026.
29. Walsh K.M., Codd V., Smirnov I.V., Rice T., Decker P.A., Hansen H.M., Kollmeyer T., Kosel M.L., Molinaro A.M., McCoy L.S., et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 2014, 46:731-735.
30. Codd V., Nelson C.P., Albrecht E., Mangino M., Deelen J., Buxton J.L., Hottenga J.J., Fischer K., Esko T., Surakka I., et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013, 45:422-427. 427e421-422.
31. Suva M.L., Louis D.N. Next-generation molecular genetics of brain tumours. Curr Opin Neurol 2013, 26:681-687.
32. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., de Rooi J.J., Stubbs A.P., Duijm J.E., Daemen A., Bleeker F.E., Bralten L.B., Kloosterhof N.K., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009, 69:9065-9072.
33. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
34. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477.
35. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
36. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
37. Brennan C., Momota H., Hambardzumyan D., Ozawa T., Tandon A., Pedraza A., Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4:e7752.
38. Sun Y., Zhang W., Chen D., Lv Y., Zheng J., Lilljebjorn H., Ran L., Bao Z., Soneson C., Sjogren H.O., et al. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proc Natl Acad Sci U S A 2014, 111:3538-3543.
39. Bredel M., Scholtens D.M., Yadav A.K., Alvarez A.A., Renfrow J.J., Chandler J.P., Yu I.L., Carro M.S., Dai F., Tagge M.J., et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011, 364:627-637.
40. Morris L.G., Kaufman A.M., Gong Y., Ramaswami D., Walsh L.A., Turcan S., Eng S., Kannan K., Zou Y., Peng L., et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013, 45:253-261.
41. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., Tsoi J., Clark O., Oldrini B., Komisopoulou E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
42. Turcan S., Fabius A.W., Borodovsky A., Pedraza A., Brennan C., Huse J., Viale A., Riggins G.J., Chan T.A. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 2013, 4:1729-1736.
43. Brown P.D., Krishnan S., Sarkaria J.N., Wu W., Jaeckle K.A., Uhm J.H., Geoffroy F.J., Arusell R., Kitange G., Jenkins R.B., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: north central cancer treatment group study N0177. J Clin Oncol 2008, 26:5603-5609.
44. van den Bent M.J., Brandes A.A., Rampling R., Kouwenhoven M.C., Kros J.M., Carpentier A.F., Clement P.M., Frenay M., Campone M., Baurain J.F., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009, 27:1268-1274.
45. Lassman A.B., Rossi M.R., Raizer J.J., Abrey L.E., Lieberman F.S., Grefe C.N., Lamborn K., Pao W., Shih A.H., Kuhn J.G., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005, 11:7841-7850.
46. Neyns B., Sadones J., Joosens E., Bouttens F., Verbeke L., Baurain J.F., D'Hondt L., Strauven T., Chaskis C., In't Veld P., et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009, 20:1596-1603.
47. Thiessen B., Stewart C., Tsao M., Kamel-Reid S., Schaiquevich P., Mason W., Easaw J., Belanger K., Forsyth P., McIntosh L., et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010, 65:353-361.
48. Snuderl M., Fazlollahi L., Le L.P., Nitta M., Zhelyazkova B.H., Davidson C.J., Akhavanfard S., Cahill D.P., Aldape K.D., Betensky R.A., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20:810-817.
49. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353:2012-2024.
50. Fenton T.R., Nathanson D., Ponte de Albuquerque C., Kuga D., Iwanami A., Dang J., Yang H., Tanaka K., Oba-Shinjo S.M., Uno M., et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 2012, 109:14164-14169.
51. Koul D., Shen R., Kim Y.W., Kondo Y., Lu Y., Bankson J., Ronen S.M., Kirkpatrick D.L., Powis G., Yung W.K. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010, 12:559-569.
52. Kreisl T.N., Lassman A.B., Mischel P.S., Rosen N., Scher H.I., Teruya-Feldstein J., Shaffer D., Lis E., Abrey L.E. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009, 92:99-105.
53. Jackson C.M., Lim M., Drake C.G. Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 2014, 20:3651-3659.
54. Shi Q., Qin L., Wei W., Geng F., Fan R., Shin Y.S., Guo D., Hood L., Mischel P.S., Heath J.R. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci U S A 2012, 109:419-424.
55. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
56. Szerlip N.J., Pedraza A., Chakravarty D., Azim M., McGuire J., Fang Y., Ozawa T., Holland E.C., Huse J.T., Jhanwar S., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 2012, 109:3041-3046.
57. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
58. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
59. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., Prestegarden L., Rosland G., Thorsen F., Stuhr L., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008, 122:761-768.
60. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011, 71:4055-4060.
61. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
62. Inda M.M., Bonavia R., Mukasa A., Narita Y., Sah D.W., Vandenberg S., Brennan C., Johns T.G., Bachoo R., Hadwiger P., et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010, 24:1731-1745.
63. Hunter C., Smith R., Cahill D.P., Stephens P., Stevens C., Teague J., Greenman C., Edkins S., Bignell G., Davies H., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006, 66:3987-3991.
64. Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193.
65. Mitchell D.A., Fecci P.E., Sampson J.H. Immunotherapy of malignant brain tumors. Immunol Rev 2008, 222:70-100.
66. Champiat S., Ferte C., Lebel-Binay S., Eggermont A., Soria J.C. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014, 3:e27817.